Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.
about
A simplified approach to predict CYP3A-mediated drug-drug interactions at early drug discovery: validation with clinical data.The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans.Current and future therapies for hepatitis C virus infection: from viral proteins to host targets.Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV.
P2860
Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Cross-species absorption, meta ...... e 1 NS3/4A protease inhibitor.
@en
Cross-species absorption, meta ...... e 1 NS3/4A protease inhibitor.
@nl
type
label
Cross-species absorption, meta ...... e 1 NS3/4A protease inhibitor.
@en
Cross-species absorption, meta ...... e 1 NS3/4A protease inhibitor.
@nl
prefLabel
Cross-species absorption, meta ...... e 1 NS3/4A protease inhibitor.
@en
Cross-species absorption, meta ...... e 1 NS3/4A protease inhibitor.
@nl
P2093
P2860
P1433
P1476
Cross-species absorption, meta ...... e 1 NS3/4A protease inhibitor.
@en
P2093
Chan-Loi Yong
Francois Otis
Gordon Bolger
Hélène Montpetit
Jianmin Duan
Josie De Marte
Ma'an Amad
Manon Rhéaume
Martin Jutras
Michael G Cordingley
P2860
P304
P356
10.3109/00498254.2011.611546
P407
P577
2011-10-11T00:00:00Z